Institute for Wealth Management LLC. Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Institute for Wealth Management LLC. purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 580,997 shares of the company's stock, valued at approximately $3,928,000. Institute for Wealth Management LLC. owned about 0.15% of Recursion Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC purchased a new stake in shares of Recursion Pharmaceuticals in the third quarter valued at $25,000. Decker Retirement Planning Inc. purchased a new stake in Recursion Pharmaceuticals in the 4th quarter worth about $26,000. GAMMA Investing LLC lifted its stake in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC boosted its position in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after buying an additional 4,091 shares during the period. Finally, KBC Group NV grew its stake in shares of Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company's stock valued at $50,000 after buying an additional 3,377 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the transaction, the chief financial officer now directly owns 1,499,631 shares of the company's stock, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Blake Borgeson sold 11,447 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total transaction of $87,455.08. Following the completion of the transaction, the director now directly owns 7,066,113 shares of the company's stock, valued at $53,985,103.32. This trade represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 15.75% of the company's stock.

Recursion Pharmaceuticals Trading Up 0.1 %

NASDAQ:RXRX traded up $0.01 during midday trading on Monday, hitting $7.25. The stock had a trading volume of 15,384,442 shares, compared to its average volume of 17,069,529. The stock has a 50-day moving average of $7.03 and a 200 day moving average of $6.91. The company has a market capitalization of $2.83 billion, a price-to-earnings ratio of -4.74 and a beta of 0.86. Recursion Pharmaceuticals, Inc. has a one year low of $5.60 and a one year high of $15.74. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals's quarterly revenue was up 147.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.43) EPS. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Wall Street Analysts Forecast Growth

RXRX has been the subject of a number of research analyst reports. Needham & Company LLC reissued a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.